{"id":156027,"date":"2021-10-05T18:19:03","date_gmt":"2021-10-05T22:19:03","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/tcr%c2%b2-therapeutics-presents-preclinical-data-on-il-15-enhanced-trucs-at-aacr-virtual-special-conference-on-tumor-immunology-immunotherapy\/"},"modified":"2024-08-18T11:43:29","modified_gmt":"2024-08-18T15:43:29","slug":"tcr%c2%b2-therapeutics-presents-preclinical-data-on-il-15-enhanced-trucs-at-aacr-virtual-special-conference-on-tumor-immunology-immunotherapy","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/tcr%c2%b2-therapeutics-presents-preclinical-data-on-il-15-enhanced-trucs-at-aacr-virtual-special-conference-on-tumor-immunology-immunotherapy.php","title":{"rendered":"TCR\u00b2 Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Special Conference on Tumor Immunology &amp; Immunotherapy"},"content":{"rendered":"<p><![CDATA[CAMBRIDGE, Mass., Oct.  05, 2021  (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the e-poster presentation of new preclinical data at the American Association for Cancer Research (AACR) Virtual Special Conference on Tumor Immunology and Immunotherapy, taking place October 5-6, 2021. The e-poster titled \u201cExpression of an IL-15 Receptor Fusion Protein Enhances the Persistence of TRuC-T Cells\u201d highlights preclinical data on the Company\u2019s proprietary mesothelin-directed T Cell Receptor Fusion Construct (TRuC\u00ae) T cells that express IL-15-based enhancements as a strategy for improving T cell persistence. The co-expression of these IL-15 enhancements enriched for na\u00efve and central memory T cells, upregulated the stemness-associated transcription factor TCF-1 and increased TRuC-T cell proliferation upon repeated stimulation with mesothelin-expressing cancer cell lines. In addition, IL-15 promoted the survival of TRuC-T cells in the absence of T cell receptor (TCR) or exogenous cytokine stimulation. In a mesothelioma xenograft mouse model, IL-15 co-expression resulted in a higher number of TRuC-T cells in the tumor and significantly increased their persistence in peripheral blood. The administration of a single dose of IL-15 enhanced TRuC-T cells cleared tumors in all mice and fully protected them from tumor rechallenge.]]><\/p>\n<p>More here:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/www.globenewswire.com\/news-release\/2021\/10\/05\/2308808\/0\/en\/TCR-Therapeutics-Presents-Preclinical-Data-on-IL-15-Enhanced-TRuCs-at-AACR-Virtual-Special-Conference-on-Tumor-Immunology-Immunotherapy.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"TCR\u00b2 Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Special Conference on Tumor Immunology &amp; Immunotherapy\">TCR\u00b2 Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Special Conference on Tumor Immunology &amp; Immunotherapy<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>More here: TCR\u00b2 Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Special Conference on Tumor Immunology &amp; Immunotherapy <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/tcr%c2%b2-therapeutics-presents-preclinical-data-on-il-15-enhanced-trucs-at-aacr-virtual-special-conference-on-tumor-immunology-immunotherapy.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-156027","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/156027"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=156027"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/156027\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=156027"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=156027"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=156027"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}